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Global Framework for Noncommunicable Diseases:
How Can We Monitor Palliative Care?
Liliana De Lima, MHA,1 Roberto Wenk, MD,2 Eric Krakauer, MD,3 Frank Ferris, MD,4
Michael Bennett, MD,5 Scott Murray, MD,6 Eduardo Bruera, MD,7 and Lukas Radbruch, MD8
Dear Editor:
Noncommunicable diseases (NCDs) are the leading global
cause of death worldwide. Of the 57 million deaths that oc-
curred in 2008, 36 million were due to NCDs, mainly car-
diovascular diseases, cancers, diabetes, and chronic lung
diseases.1 The World Health Organization (WHO) Action
Plan for the Global Strategy for the Prevention and Control of
Noncommunicable Diseases2 addresses key components of
surveillance, prevention, and care. The proposed monitoring
framework includes indicators of outcomes, exposures, and
health systems capacity and response.
For several years the palliative care community has advo-
cated for systematic monitoring of palliative care at national
and global levels. Although several palliative care organizations
report on the status of palliative care development,3,4 WHO
member states have no obligation to monitor or report on pal-
liative care, and available reports have had limited impact on
the provision of care. The WHO revised discussion paper on the
global monitoring framework5 includes a palliative care indi-
cator, a step forward that is welcomed by the international
palliative care community. The proposed indicator is:
Access to palliative care assessed by morphine-equivalent con-
sumption of strong opioid analgesics (excluding methadone) per
death from cancer.
The inclusion of a palliative care indicator is a crucial step
forward in that it acknowledges that pain relief and palliative
care as among the top 12 issues on the global health agenda.
However, the proposed indicator has several major limita-
tions and weaknesses. This letter reviews these limitations
and describes a proposal submitted to WHO to strengthen the
indicator and eliminate some of these weaknesses.
1. The quality and scope of the cancer registries in devel-
oping countries are inadequate. As stated in the revised
WHO discussion paper: ‘‘.there remains a notable lack
of high-quality population based cancer registries in
Africa, Asia and Latin America, with approximately 1, 4
and 6 per cent of the populations of these respective
regions being monitored.’’ (12) Another WHO publica-
tion indicates there are more than 200 population-based
cancer registries covering only about 5% of the world’s
population, and the proportion is much greater in de-
veloped countries than in developing ones.6 Moreover,
in developing countries, registries are likely to cover
primarily urban areas. It is quite likely that cancer reg-
istry data in these regions systematically underestimate
both incidence and mortality.
2. Using cancer mortality would distort the real need for
opioids. In addition to treatment of cancer pain, strong
opioids are also essential for the treatment of pain from
other causes and of other symptoms such as dyspnea
as well as for the treatment of drug dependence syn-
drome (substitution therapy).
3. Even if this indicator would be appropriate, there are
statistical weaknesses of such a combination: cancer
population data (the denominator) are reported in periods
of 5 or 10 years, whereas drug consumption (the nomi-
nator) is reported annually. An indicator based on the
combination of such factors would result in inaccuracies
and misinformation about the real status of palliative care.
4. The indicator wrongly suggests that palliative care is
suitable only for cancer patients. However, patients
with other major NCDs, such as advanced cardiovas-
cular, renal, liver, lung, and neurologic disease, and
patients with advanced acquired immune deficiency
syndrome (AIDS), also require palliative care.
5. The indicator wrongly suggests that palliative care is
equivalent to pain control and does not take into
consideration other intrinsic components of palliative
care, such as treatment of physical symptoms other
than pain and psychosocial and spiritual support. Thus
it would generate rough figures about pain treatment
and less precise figures about palliative care.
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6. Opioid consumption is a weak indicator of access to
palliative care. Data may indicate that, in developed
countries, only about 0.4% of strong opioids are
consumed in palliative care, whereas in fact most of
them are used for acute and chronic noncancer
pain.7 The indicator may also suggest the false idea
that an increase in opioid consumption is equal to
(or sufficient for) the provision of good palliative
care.
Based on the limitations stated above, the International
Association for Hospice and Palliative Care (IAHPC) and
several palliative care organizations proposed to WHO a
modification to improve the indicator to monitor the devel-
opment and progress of palliative care:
Access to palliative care assessed by per capita morphine-equivalent
consumption of strong opioid analgesics (excluding methadone).
This change to the proposed indicator (morphine equiva-
lent opioid consumption per capita) has several advantages:
1. It would avoid limitations 1 through 4 mentioned in
the sections above.
2. The total population-based denominator would pro-
vide more accurate information as to the adequacy of
opioid availability for all patients in need.
3. The vast majority of the countries in the world have sys-
tems in place and already report consumption of opioids
on an annual basis to the International Narcotics Control
Board (INCB) as part of their obligations under the Single
Convention on Narcotic Drugs. This indicator would not
generate any additional burden on member states.
Limitations 5 and 6 would persist and this indicator would
provide only a rough estimate of the availability of opioids for
pain relief.
To establish how the two indicators would differ in country
monitoring, an analysis was carried out by IAHPC using
consumption, population, and mortality data from 30 selected
countries of the world with information provided by the
WHO Department of Essential Medicines and Health Pro-
ducts and expert advice from Willem Scholten, PharmD.
MPA, using consumption, population, and mortality data
from 30 selected countries of the world. These countries were
selected from all the geographical regions and the socioeco-
nomic levels of development.
Data were obtained from available resources (Table 1):
 Total morphine equivalent consumption for fentanyl,
hydromorphone, morphine, oxycodone, and pethidine
was obtained.8
 Population data were identified.9
Table 1. Opioid Consumption and Mortality Data
Country
Total Meq
consumption
2010 (mg)a
Population
2010
Consumption Meq
mg/ per capita
per year (2010)
Cancer
mortality
(Globocan 2008)
Consumption
Meq mg/cancer
death per year (2010)
Cancer mortality
per 1000
inhabitants
Argentina 602,235,000 40,500,000 14.87 60,500 9954.3 1.49
Australia 4,664,240,000 22,400,000 208.225 40,889 114,070.8 1.83
Brasil 2,538,222,300 193,300,000 13.131 102,233 24,827.8 0.53
Canada 22,413,009,300 34,100,000 657.273 38,242 586,083.6 1.12
Colombia 308,581,000 45,500,000 6.782 16,674 18,506.7 0.37
China 3,826,966,000 1,338,100,000 2.86 1,222,199 3131.2 0.91
Estonia 23,912,200 1,300,000 18.394 3535 6764.4 2.72
Georgia 10,106,200 4,600,000 2.197 5806 1740.6 1.26
Germany 31,822,531,200 81,600,000 389.982 212,189 149,972.6 2.60
Guatemala 29,001,600 14,400,000 2.014 9120 3180.0 0.63
Hungary 763,060,000 10,000,000 76.306 31,947 23,885.2 3.19
Japan 3,748,184,440 127,400,000 29.4206 342,214 10,952.8 2.69
Jordan 56,576,000 6,500,000 8.704 3445 16,422.6 0.53
India 362,584,000 1,188,800,000 0.305 633,455 572.4 0.53
Kenya 67,240,000 40,000,000 1.681 22,115 3040.5 0.55
Malaysia 181,260,800 28,900,000 6.272 20,130 9004.5 0.70
Malawi 33,171,600 15,400,000 2.154 11,522 2879.0 0.75
Mexico 715,250,200 110,600,000 6.467 77,708 9204.3 0.70
Peru 65,431,000 29,500,000 2.218 24,828 2635.4 0.84
Romania 201,304,500 21,500,000 9.363 46,301 4347.7 2.15
Serbia 292,408,800 7,300,000 40.056 24,345 12,011.0 3.33
Singapore 58,486,800 5,100,000 11.468 6106 9578.6 1.20
South Africa 2,181,178,900 49,900,000 43.711 51,436 42,405.7 1.03
Ukraine 66,555,000 45,900,000 1.45 86,621 768.3 1.89
Uganda 25,485,200 33,800,000 0.754 21,317 1195.5 0.63
United Kingdom 9,304,809,000 62,200,000 149.595 156,354 59,511.2 2.51
United States 1.49223E + 11 309,600,000 481.986 565,644 263,810.6 1.83
Vietnam 120,370,600 88,900,000 1.354 82,006 1467.8 0.92
aThe morphine equivalence ratios for the different opioids and their DDDs are those used by the WHO Collaborating Centre in for Drug
Statistics Methodology in Oslo, Norway (see reference 10). The ratios used in this analysis may vary from others and their differences are not
the focus of this letter.
Meq, morphine equivalence.
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 Total consumption per capita of each medication was
converted to ‘‘morphine equivalents’’ using their rela-
tive effectiveness as expressed by WHO’s Defined Daily
Dose (DDD).10 (The DDD is a unit of measurement used
for comparative and statistical purposes and does not
necessarily reflect the Prescribed Daily Dose or the best
treatment approach. The adequate therapeutic dose is a
medical decision determined by each case.)
 Using the cancer mortality data from the IARC/WHO
Globocan Database 2008, the opioid consumption per
cancer death was calculated.11
The morphine equivalent consumption per capita indicates
that Canada, the United States, Germany, Australia, and the
United Kingdom reported above 140 mg per capita in 2010.
This is consistent with consumption trends from previous
years. Of the selected countries, 12 countries (China, Peru,
Georgia, Malawi, Guatemala, Kenya, Ukraine, Vietnam,
Uganda, India, Romania, and Malawi) reported consumption
of less than 2 mg per capita.
In comparison, morphine equivalent consumption per
cancer deaths would result in extremely large numbers. For
example, every cancer patient who died in Canada would
seem to have consumed more than 586,000 mg, almost 900
times the consumption per capita. In the same way, the in-
dicator would imply that each cancer patient who died in
Colombia consumed the equivalent of more than 18,000 mgs
per year, almost 3,000 times the consumption per capita.
Similar distortion would occur in data for all the countries
included in the study (Table 2).
More important, countries with lower socioeconomic levels
of development are at a further disadvantage, as they have a
higher ratio, placing them in the top half of Table 2. This
means that the consumption per cancer death indicator for
Jordan is higher than that for Serbia or even for Japan, even
though the consumption per capita is only one-fourth and
one-third, respectively.
A denominator based on cancer mortality numbers would
be extremely and often erroneously small. Thus the resulting
indicator would overestimate the adequacy of opioid avail-
ability and negatively impact efforts to make strong opioids
accessible to all patients who need them.
The distortion between the consumption per capita and the
consumption per cancer death would occur not only in the 30
countries included in this study but in all countries; with the
distortion being proportional to the status of cancer registries
(the less the population is monitored for cancer, the greater the
distortion). This would also mean that cross-country com-
parisons would be of little value, especially between those
that have comprehensive cancer registries in place and de-
veloping countries, where 5% or less of the population is
monitored.
The consumption per cancer death indicator would further
distort the situation in countries with low socioeconomic
status. In many of these countries palliative care has been
initiated in response to the challenge of human immunode-
ficiency virus (HIV)/AIDS, in close collaboration with anti-
retroviral treatment, and palliative care services are targeted
toward this patient group. Patients with NCDs often find it
difficult to access palliative care in these countries, and most
often do not receive the opioid treatment they need. Thus the
higher consumption per cancer death indicator would di-
rectly counteract the purpose of the Global Framework, as it
would show higher values in countries where fewer patients
with NCDs receive adequate opioid treatment.
Opioid treatment is required for other indications than
cancer pain, including acute pain, pain in HIV/AIDS, post-
surgical pain, pain in women during labor, dyspnea, and
substitution therapy. Large consumption numbers with the
consumption per cancer death indicator will also negatively
impact the efforts to improve availability of opioids for these
other indications.
The palliative care community recognizes the importance
of cancer registries and advocates for and supports appro-
priate disease monitoring and reporting systems. However,
developing a palliative care indicator based on unreliable data
will lead to a weak indicator. Using opioid consumption per
capita will provide a much stronger indicator with more rel-
evance to the goals of the Global Framework.
The palliative care community is also aware that currently
there are many limitations to monitoring palliative care and it
will continue to work with member states and civil society to
support the development of palliative care globally, so that a
comprehensive, more accurate palliative care indicator can be
developed, such as:
1. Palliative care capacity (number of services and full-
time palliative care providers) per 100,000 inhabitants.
2. Proportion of national disease strategies that include
palliative care components or programs.
Table 2. Comparison between the Two Indicators
Country
Meq mg/per
capita per
year (2010)
Meq mg/
cancer death
per year (2010)
Ratio cons/
cancer deaths
cons/per
capita (2010)
Colombia 6.78 18,506.72 2728.80
Brazil 13.13 24,827.82 1890.78
Jordan 8.70 16,422.64 1886.79
India 0.31 572.39 1876.69
Kenya 1.68 3040.47 1808.73
Uganda 0.75 1195.53 1585.59
Guatemala 2.01 3180.00 1578.95
Malaysia 6.27 9004.51 1435.67
Mexico 6.47 9204.33 1423.28
Malawi 2.15 2878.98 1336.57
Peru 2.22 2635.37 1188.17
China 2.86 3131.21 1094.83
Vietnam 1.35 1467.83 1084.07
South Africa 43.71 42,405.69 970.14
Canada 657.27 586,083.61 891.69
Singapore 11.47 9578.58 835.24
Georgia 2.20 1740.65 792.28
Argentina 14.87 9954.30 669.42
Australia 208.23 114,070.78 547.82
United States 481.99 263,810.57 547.34
Ukraine 1.45 768.35 529.89
Romania 9.36 4347.74 464.35
United Kingdom 149.60 59,511.17 397.82
Germany 389.98 149,972.58 384.56
Japan 29.42 10,952.75 372.28
Estonia 18.39 6764.41 367.75
Hungary 76.31 23,885.18 313.02
Serbia 40.06 12,011.04 299.86
cons, consumption; Meq, morphine equivalence.
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3. Proportion of university programs for health profes-
sions that include palliative care curricula in under-
graduate and programs in postgraduate levels,
including academic chairs and specialty training.
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